Oral Testosterone Undecanoate (JATENZO, Tlando, Kyzatrex) for Women
Oral Testosterone Undecanoate (TU) is emerging as a promising option for women experiencing symptoms related to androgen deficiency—a condition that can affect mood, energy, sexual desire, and musculoskeletal health, particularly around menopause or after surgical removal of the ovaries. While testosterone therapy has traditionally been associated with men, growing research is exploring how carefully managed testosterone supplementation may support women whose natural androgen levels have declined. This treatment is relevant for women facing hypoactive sexual desire disorder (HSDD), fatigue linked to low testosterone, or musculoskeletal decline, especially in perimenopausal and menopausal stages. Understanding how Oral Testosterone Undecanoate works, what the current evidence suggests, and its appropriate clinical use can help women and their healthcare providers navigate this evolving therapeutic area within a longevity and wellness framework.
How It Works
Testosterone is a key androgen hormone that influences a variety of physiological processes in women, including sexual function, mood regulation, energy metabolism, and muscle maintenance. Oral Testosterone Undecanoate is a specially formulated version of testosterone designed to be taken by mouth. Unlike older oral testosterone formulations that faced challenges with liver metabolism and inconsistent blood levels, TU is lipophilic—meaning it dissolves in fats—and is absorbed through the intestinal lymphatic system rather than directly into the liver. This unique absorption route helps bypass the liver’s first-pass metabolism, resulting in more stable and bioavailable testosterone levels in the bloodstream, with potentially less risk of liver strain.
Once absorbed, testosterone binds to intracellular androgen receptors located in various tissues such as the brain, muscle, bone, and reproductive organs. This receptor binding triggers changes in gene expression that support protein synthesis, enhance libido, improve mood, and increase overall energy. Additionally, testosterone and its metabolites act as neurosteroids within the central nervous system, modulating neurotransmitters involved in cognition, emotional well-being, and sexual desire. This combined action on multiple body systems underpins the potential benefits of TU in women with androgen deficiency.
What the Evidence Says
The bulk of clinical data on Oral Testosterone Undecanoate comes from studies in men with hypogonadism, where it has been FDA-approved and shown to effectively restore testosterone levels and improve symptoms related to low androgen. However, research specifically focused on women is more limited and still evolving, placing the evidence at what is often considered a “T3” level—meaning promising but not yet definitive.
Emerging studies from 2022 onward suggest that TU may help women with hypoactive sexual desire disorder (HSDD), a condition characterized by reduced sexual interest that causes distress. Some small clinical trials and observational reports indicate improvements in sexual function, mood, and energy with physician-supervised TU therapy in women, especially those who have undergone surgical menopause or have clinically low androgen levels. There are also indications that testosterone might support musculoskeletal health by promoting muscle protein synthesis and bone density, which are critical concerns for aging women.
However, it is important to note that robust, female-specific dosing protocols and long-term safety data are still lacking. Most studies use off-label approaches adapted from male dosing guidelines, with close monitoring recommended. Research also highlights variability in individual responses and the need for personalized treatment plans. Potential side effects and risks, such as changes in lipid profiles or androgenic effects like acne or hair changes, underscore the importance of physician supervision.
Clinical Context
In clinical practice, Oral Testosterone Undecanoate for women is typically considered when symptoms of androgen deficiency are clearly identified and other causes have been ruled out. It may be used in cases of surgical menopause, confirmed low serum testosterone levels, or diagnosed HSDD. Treatment always requires careful evaluation by a qualified healthcare provider who can tailor dosing, monitor hormone levels, and observe for side effects.
Monitoring often includes regular blood tests to measure testosterone levels and other relevant markers, as well as assessments of symptom improvement and any adverse effects. Because TU bypasses the liver’s first-pass effect, it may be preferred over older oral testosterone formulations, but injectable or transdermal options are also available and might be considered depending on patient preference and clinical judgment.
Within a comprehensive longevity and wellness program like that promoted by Tomorrow Today Longevity, TU can be integrated alongside lifestyle modifications, peptide therapies, and other hormone optimization strategies to create a synergistic effect aimed at restoring androgen balance and supporting overall vitality.
Key Takeaways
- Oral Testosterone Undecanoate is a lipophilic oral testosterone formulation absorbed via the lymphatic system, offering stable testosterone levels with potentially less liver strain.
- Emerging research suggests TU may support women with androgen deficiency-related symptoms such as low sexual desire, mood changes, fatigue, and musculoskeletal decline.
- Clinical use in women remains off-label, requiring physician supervision for dosing, monitoring, and safety assessment.
- TU may be a valuable tool within a broader longevity and hormone optimization framework, but more female-specific studies are needed to refine protocols and confirm long-term safety.
Frequently Asked Questions
Is Oral Testosterone Undecanoate safe for women?
When used under the supervision of a qualified healthcare provider, Oral Testosterone Undecanoate may be safe for women with diagnosed androgen deficiency. However, long-term safety data in women are limited, so careful monitoring is essential to manage potential side effects.
How is dosing determined for women using TU?
Dosing is personalized and typically guided by a physician based on symptom severity, baseline testosterone levels, and treatment response. Since female-specific dosing protocols are still being developed, treatment usually starts low and is adjusted cautiously.
Can TU improve sexual desire in menopausal women?
Research suggests that Oral Testosterone Undecanoate may help improve hypoactive sexual desire disorder in some women, particularly those with surgical menopause or confirmed low androgen levels. However, individual responses vary, and it should be part of a comprehensive treatment plan.
By understanding the current landscape of Oral Testosterone Undecanoate for women, individuals and healthcare providers can make informed decisions about its potential role in supporting healthy aging and hormonal balance within a personalized longevity strategy.